• Mashup Score: 2

    When I started as a specialty registrar in clinical genetics in 2013, genetic testing for rare disorders in the NHS involved single gene tests. These were performed at different specialist laboratories, by the labour-intensive process of Sanger sequencing. Due to the financial cost, sequencing was only ordered through clinical genetics departments, and requests were scrutinised at a departmental…

    Tweet Tweets with this article
    • "We recommend that whole genome sequencing should be used early in the 'diagnostic odyssey,' before invasive tests so that patients can benefit from the power of this new technology." Katherine Schon describes what her team learnt from new #BMJResearch https://t.co/wBTV7zVO8w

  • Mashup Score: 25

    When I started as a specialty registrar in clinical genetics in 2013, genetic testing for rare disorders in the NHS involved single gene tests. These were performed at different specialist laboratories, by the labour-intensive process of Sanger sequencing. Due to the financial cost, sequencing was only ordered through clinical genetics departments, and requests were scrutinised at a departmental…

    Tweet Tweets with this article
    • "We recommend that whole genome sequencing should be used early in the 'diagnostic odyssey,' before invasive tests so that patients can benefit from the power of this new technology." Katherine Schon describes what her team learnt from new #BMJResearch https://t.co/RlF7cwPrH1

  • Mashup Score: 6

    Objective To examine the risk of urogenital, colorectal, and neurological cancers after a first diagnosis of acute urinary retention. Design Nationwide population based cohort study. Setting All hospitals in Denmark. Participants 75 983 patients aged 50 years or older with a first hospital admission for acute urinary retention during 1995-2017. Main outcome measures Absolute risk of…

    Tweet Tweets with this article
    • A first diagnosis of acute urinary retention in patients aged 50 years or older was a clinical marker not only for prostate cancer but also for other urogenital cancers and colorectal and neurological cancers, according to new #BMJResearch https://t.co/Xe3cnyXo1O @dceaarhus